Back

Bristol Myers Squibb reports two-year Sotyktu results in psoriatic arthritis trial

Verifying
  • Bristol Myers Squibb released two-year POETYK PsA-2 results for Sotyktu in active psoriatic arthritis.
  • Continuous-treatment patients recorded Week 104 observed ACR20/50/70 rates of 76.2%, 52.6% and 34.6%.
  • The Phase 3 trial previously reported a Week 16 ACR20 result of 54.2% versus 39.4% for placebo.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Bristol Myers Squibb reports two-year Sotyktu results in psoriatic arthritis trial - CoinPost Terminal